Unverified record. The outcome below was inferred from the share-price reaction around this date. Nobody has confirmed it against an FDA, SEC or company document, and it may be wrong: we have published at least one inferred outcome that turned out to be impossible (see corrections). Treat it as a price observation, not as a regulatory fact. Verified decisions on this site always link a primary source.
RHHBY FDA Decision outcome unverified · 2025-02-04
Rebuilt daily·next FDA decision on the calendar
Price into the decision (T-120)
Daily close, T-120 (8/20/24) through T+5. Run-up high $42.33 on 9/9/24, low $34.24 on 12/25/24 (T-120 to T-1). FDA decision 2/4/25. Historical price action, not a forecast.
Decision facts
FDA decision date2025-02-04
OutcomeUnconfirmed · price consistent with approval~ price-only (validating)
Decision-day move+0.8%
T-120 run-up (low→high)+6.0% ($34.24→$40.57)
ValidationOutcome consistent with price; primary-source verification in progress.
Market-cap tierLarge
Cohort decision-day move (history)1.0% median (n=827)
Cohort move is the historical median absolute decision-day move for this market-cap tier across our run-up study. History, not a prediction.